Targeting leukotriene B4 in inflammation

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 1, 2014, Pages 79-93

  Di Gennaro, Antonio ^a   Haeggström, Jesper Z ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

5 lipoxygenase; Arachidonic acid; Inflammatory diseases; Leukotriene A4 hydrolase

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5 [2 (2 CARBOXYETHYL) 3 [6 (4 METHOXYPHENYL) 5 HEXENYLOXY]PHENOXY]VALERIC ACID; 5 ETHYL 2 HYDROXY 4 [6 METHYL 6 (1H TETRAZOL 5 YL)HEPTYLOXY]ACETOPHENONE; ADENYLATE CYCLASE; AMELUBANT; ARACHIDONATE 5 LIPOXYGENASE; ATRELEUTON; BESTATIN; CAPTOPRIL; ETALOCIB; FIBOFLAPON; HYDROLASE; JNJ 26993135; LEUKOTRIENE B4 RECEPTOR; PHOSPHOLIPASE A2; QUIFLAPON; SC 57461A; SETILEUTON; UNCLASSIFIED DRUG; ZILEUTON;

ACUTE CORONARY SYNDROME; ASTHMA; BIOSYNTHESIS; CALCIUM CELL LEVEL; CELL MEMBRANE; CHEMOTAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL STUDY; CRYSTAL STRUCTURE; DRUG TARGETING; ENTERITIS; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS;

ARACHIDONATE 5-LIPOXYGENASE; HUMANS; INFLAMMATION; LEUKOTRIENE B4;

EID: 84890324535     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.843671     Document Type: Review

References (126)

1. Haeggstrom JZ, Funk CD. Lipoxygenase and leukotriene pathways: Biochemistry, biology, and roles in disease. Chem Rev 2011;111(10):5866-98
2. Nakamura M, Shimizu T. Leukotriene receptors. Chem Rev 2011;111(10):6231-98
3. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980;288(5790):484-6
4. Ford-Hutchinson AW, Bray MA, Doig MV, et al. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980;286(5770):264-5
5. Palmblad J, Malmsten CL, Uden AM, et al. Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood 1981;58(3):658-61
6. Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 1987;237(4819):1171-6
7. Ryan A, Godson C. Lipoxins: Regulators of resolution. Curr Opin Pharmacol 2010;10(2):166-72
8. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 2011;111(10):5922-43
9. Borgeat P, Samuelsson B. Metabolism of arachidonic acid in polymorphonuclear leukocytes. Structural analysis of novel hydroxylated compounds. J Biol Chem 1979;254(16):7865-9
10. Borgeat P, Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: Unstable intermediate in formation of dihydroxy acids. Proc Natl Acad Sci USA 1979;76(7):3213-17
11. Lee SP, Serezani CH, Medeiros AI, et al. Crosstalk between prostaglandin E2 and leukotriene B4 regulates phagocytosis in alveolar macrophages via combinatorial effects on cyclic AMP. J Immunol 2009;182(1):530-7
12. Okamoto F, Saeki K, Sumimoto H, et al. Leukotriene B4 augments and restores FcgRs-dependent phagocytosis in macrophages. J Biol Chem 2010;285(52):41113-21
13. Serezani CH, Kane S, Collins L, et al. Macrophage dectin-1 expression is controlled by leukotriene B4 via a GMCSF/ PU.1 axis. J Immunol 2012;189(2):906-15
14. Flamand L, Tremblay MJ, Borgeat P. Leukotriene B4 triggers the in vitro and in vivo release of potent antimicrobial agents. J Immunol 2007;178(12):8036-45
15. Gaudreault E, Gosselin J. Leukotriene B4 induces release of antimicrobial peptides in lungs of virally infected mice. J Immunol 2008;180(9):6211-21
16. Wan M, Sabirsh A, Wetterholm A, et al. Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: Novel lipid-peptide interactions in innate immune responses. Faseb J 2007;21(11):2897-905
17. Widegren H, Andersson M, Borgeat P, et al. LTB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects. Respir Med 2011;105(7):997-1006
18. Costa MF, de Souza-Martins R, de Souza MC, et al. Leukotriene B4 mediates gd T lymphocyte migration in response to diverse stimuli. J Leukoc Biol 2009;87(2):323-32
19. Goodarzi K, Goodarzi M, Tager AM, et al. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 2003;4(10):965-73
20. Islam SA, Thomas SY, Hess C, et al. The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood 2006;107(2):444-53
21. Kihara Y, Yokomizo T, Kunita A, et al. The leukotriene B4 receptor, BLT1, is required for the induction of experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 2010;394(3):673-8
22. Klein E, Liu A, Claesson HE. Activation of innate immunity by the leukotriene B4 inhibits EBV induced B-cell transformation in cord-blood derived mononuclear cultures. Immunol Lett 2008;116(2):174-7
23. Liu A, Claesson HE, Mahshid Y, et al. Leukotriene B4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures. Blood 2008;111(5):2693-703
24. Tager AM, Bromley SK, Medoff BD, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003;4(10):982-90
25. Devchand PR, Keller H, Peters JM, et al. The PPARa-leukotriene B4 pathway to inflammation control. Nature 1996;384(6604):39-43
26. Orasanu G, Ziouzenkova O, Devchand PR, et al. The peroxisome proliferator-Activated receptor-g agonist pioglitazone represses inflammation in a peroxisome proliferator-Activated receptor-A-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol 2008;52(10):869-81
27. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007;357(18):1841-54
28. Ahmadzadeh N, Shingu M, Nobunaga M, Tawara T. Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fluids. Inflammation 1991;15(6):497-503
29. Gheorghe KR, Korotkova M, Catrina AI, et al. Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. Arthritis Res Ther 2009;11(3):R83
30. Klickstein LB, Shapleigh C, Goetzl EJ. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J Clin Invest 1980;66(5):1166-70
31. Rae SA, Davidson EM, Smith MJ. Leukotriene B4, an inflammatory mediator in gout. Lancet 1982;2(8308):1122-4
32. Chou RC, Kim ND, Sadik CD, et al. Lipid-cytokine-chemokine cascade drives neutrophil recruitment in a murine model of inflammatory arthritis. Immunity 2010;33(2):266-78
33. Kim ND, Chou RC, Seung E, et al. A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med 2006;203(4):829-35
34. Sadik CD, Kim ND, Iwakura Y, Luster AD. Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcgR signaling. Proc Natl Acad Sci USA 2012;109(46):E3177-85
35. Anderson GD, Keys KL, De Ciechi PA, Masferrer JL. Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. Inflamm Res 2009;58(2):109-17
36. Chen M, Lam BK, Luster AD, et al. Joint tissues amplify inflammation and alter their invasive behavior via leukotriene B4 in experimental inflammatory arthritis. J Immunol 2010;185(9):5503-11
37. Shao WH, Del Prete A, Bock CB, Haribabu B. Targeted disruption of leukotriene B4 receptors BLT1 and BLT2: A critical role for BLT1 in collagen-induced arthritis in mice. J Immunol 2006;176(10):6254-61
38. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10(3):181-93
39. Tong WG, Ding XZ, Hennig R, et al. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin Cancer Res 2002;8(10):3232-42
40. Hoque A, Lippman SM, Wu TT, et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: A potential target for prevention. Carcinogenesis 2005;26(4):785-91
41. Matsuyama M, Yoshimura R, Mitsuhashi M, et al. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol 2004;24(4):821-7
42. De Caterina R, Mazzone A, Giannessi D, et al. Leukotriene B4 production in human atherosclerotic plaques. Biomed Biochim Acta 1988;47(10-11):S182-5
43. Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 1998;97(24):2406-13
44. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003;100(3):1238-43
45. Qiu H, Gabrielsen A, Agardh HE, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 2006;103(21):8161-6
46. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 2005;4(8):664-72
47. Cao RY, St Amand T, Grabner R, et al. Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis 2009;203(2):395-400
48. Yu Z, Crichton I, Tang SY, et al. Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc Natl Acad Sci USA 2012;109(17):6727-32
49. Zhao L, Moos MP, Grabner R, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004;10(9):966-73
50. Houard X, Ollivier V, Louedec L, et al. Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus. Faseb J 2009;23(5):1376-83
51. Ahluwalia N, Lin AY, Tager AM, et al. Inhibited aortic aneurysm formation in BLT1-deficient mice. J Immunol 2007;179(1):691-7
52. Kristo F, Hardy GJ, Anderson TJ, et al. Pharmacological inhibition of BLT1 diminishes early abdominal aneurysm formation. Atherosclerosis 2010;210(1):107-13
53. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: From cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006;58(3):375-88
54. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 2009;50(Suppl):S237-42
55. Clark JD, Schievella AR, Nalefski EA, Lin LL. Cytosolic phospholipase A2. J Lipid Mediat Cell Signal 1995;12(2-3):83-117
56. Gilbert NC, Bartlett SG, Waight MT, et al. The structure of human 5-lipoxygenase. Science 2011;331(6014):217-19
57. Luo M, Jones SM, Phare SM, et al. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem 2004;279(40):41512-20
58. Werz O, Klemm J, Samuelsson B, Radmark O. 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc Natl Acad Sci USA 2000;97(10):5261-6
59. Werz O, Szellas D, Steinhilber D, Radmark O. Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-Activated protein kinase 2 (MK2). J Biol Chem 2002;277(17):14793-800
60. Luo M, Jones SM, Flamand N, et al. Phosphorylation by protein kinase a inhibits nuclear import of 5-lipoxygenase. J Biol Chem 2005;280(49):40609-16
61. Pergola C, Rogge A, Dodt G, et al. Testosterone suppresses phospholipase D, causing sex differences in leukotriene biosynthesis in human monocytes. Faseb J 2011;25(10):3377-87
62. Evans JF, Ferguson AD, Mosley RT, Hutchinson JH. What's all the FLAP about?: 5-lipoxygenase-Activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 2008;29(2):72-8
63. Rakonjac M, Fischer L, Provost P, et al. Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production. Proc Natl Acad Sci USA 2006;103(35):13150-5
64. Rudberg PC, Tholander F, Thunnissen MM, Haeggstrom JZ. Leukotriene A4 hydrolase/ aminopeptidase. Glutamate 271 is a catalytic residue with specific roles in two distinct enzyme mechanisms. J Biol Chem 2002;277(2):1398-404
65. Mueller MJ, Blomster M, Oppermann UC, et al. Leukotriene A4 hydrolase: Protection from mechanism-based inactivation by mutation of tyrosine-378. Proc Natl Acad Sci USA 1996;93(12):5931-5
66. Griffin KJ, Gierse J, Krivi G, Fitzpatrick FA. Opioid peptides are substrates for the bifunctional enzyme LTA4 hydrolase/aminopeptidase. Prostaglandins 1992;44(3):251-7
67. Snelgrove RJ, Jackson PL, Hardison MT, et al. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010;330(6000):90-4
68. Yokomizo T, Izumi T, Chang K, et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997;387(6633):620-4
69. Ott VL, Cambier JC, Kappler J, et al. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol 2003;4(10):974-81
70. Heller EA, Liu E, Tager AM, et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 2005;112(4):578-86
71. Qiu H, Johansson AS, Sjostrom M, et al. Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4. Proc Natl Acad Sci USA 2006;103(18):6913-18
72. Nieves D, Moreno JJ. Role of 5-lipoxygenase pathway in the regulation of RAW 264.7 macrophage proliferation. Biochem Pharmacol 2006;72(8):1022-30
73. Watanabe S, Yamasaki A, Hashimoto K, et al. Expression of functional leukotriene B4 receptors on human airway smooth muscle cells. J Allergy Clin Immunol 2009;124(1):59-65; e1-3
74. Yokomizo T, Kato K, Terawaki K, et al. A second leukotriene B4 receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000;192(3):421-32
75. Yokomizo T, Kato K, Hagiya H, et al. Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem 2001;276(15):12454-9
76. Okuno T, Iizuka Y, Okazaki H, et al. 12 (S)-Hydroxyheptadeca-5Z, 8E, 10E-Trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med 2008;205(4):759-66
77. Iizuka Y, Okuno T, Saeki K, et al. Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis. Faseb J 2010;24(12):4678-90
78. Matsunaga Y, Fukuyama S, Okuno T, et al. Leukotriene B4 receptor BLT2 negatively regulates allergic airway eosinophilia. Faseb J 2013;27(8):3306-14
79. Hegen M, Sun L, Uozumi N, et al. Cytosolic phospholipase A2a-deficient mice are resistant to collagen-induced arthritis. J Exp Med 2003;197(10):1297- 302
80. Marusic S, Leach MW, Pelker JW, et al. Cytosolic phospholipase A2a-deficient mice are resistant to experimental autoimmune encephalomyelitis. J Exp Med 2005;202(6):841-51
81. Uozumi N, Kume K, Nagase T, et al. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 1997;390(6660):618-22
82. Tai N, Kuwabara K, Kobayashi M, et al. Cytosolic phospholipase A2a inhibitor, pyrroxyphene, displays anti-Arthritic and anti-bone destructive action in a murine arthritis model. Inflamm Res 2010;59(1):53-62
83. Nagase T, Uozumi N, Aoki-Nagase T, et al. A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates. LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 2003;284(5):L720-6
84. Bellido-Reyes YA, Akamatsu H, Kojima K, et al. Cytosolic phospholipase A2 inhibition attenuates ischemia-reperfusion injury in an isolated rat lung model. Transplantation 2006;81(12):1700-7
85. Chen XS, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994;372(6502):179-82
86. Mancuso P, Nana-Sinkam P, Peters-Golden M. Leukotriene B4 augments neutrophil phagocytosis of Klebsiella pneumoniae. Infect Immun 2001;69(4):2011-16
87. Irvin CG, Tu YP, Sheller JR, Funk CD. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am J Physiol 1997;272(6 Pt 1):L1053-8
88. Peters-Golden M, Bailie M, Marshall T, et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002;165(2):229-35
89. Adamek A, Jung S, Dienesch C, et al. Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice. Eur J Pharmacol 2007;571(1):51-4
90. Yu Z, Ricciotti E, Miwa T, et al. Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury. Circ Res 2013;112(3):432-40
91. Pergola C, Werz O. 5-Lipoxygenase inhibitors: A review of recent developments and patents. Expert Opin Ther Patent 2010;20(3):355-75
92. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340(3):197-206
93. Hofmann B, Steinhilber D. 5-Lipoxygenase inhibitors: A review of recent patents (2010 - 2012). Expert Opin Ther Patent 2013;23(7):895-909
94. Tardif JC, L'Allier P L, Ibrahim R, et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 2010;3(3):298-307
95. Bernstein JA, Liu N, Knorr BA, et al. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease. Respir Med 2011;105(3):392-401
96. Byrum RS, Goulet JL, Griffiths RJ, Koller BH. Role of the 5-lipoxygenase-Activating protein (FLAP) in murine acute inflammatory responses. J Exp Med 1997;185(6):1065-75
97. Brideau C, Chan C, Charleson S, et al. Pharmacology of MK-0591 (3-[1-(4- chlorobenzyl)-3-(t-butylthio)-5-(quinolin- 2-yl-methoxy)- indol-2-yl]-2,2- dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 1992;70(6):799-807
98. Depre M, Friedman B, Tanaka W, et al. Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans. Clin Pharmacol Ther 1993;53(5):602-7
99. Bain G, King CD, Schaab K, et al. Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-Activating protein inhibitor. Br J Clin Pharmacol 2013;75(3):779-90
100. Kent SE, Boyce M, Diamant Z, et al. The 5-lipoxygenase-Activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma. Clin Exp Allergy 2013;43(2):177-86
101. Byrum RS, Goulet JL, Snouwaert JN, et al. Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- And leukotriene A4 hydrolase-deficient mice. J Immunol 1999;163(12):6810-19
102. Orning L, Krivi G, Bild G, et al. Inhibition of leukotriene A4 hydrolase/ aminopeptidase by captopril. J Biol Chem 1991;266(25):16507-11
103. Orning L, Krivi G, Fitzpatrick FA. Leukotriene A4 hydrolase. Inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes. J Biol Chem 1991;266(3):1375-8
104. Labaudiniere R, Hilboll G, Leon-Lomeli A, et al. Omega-[(omegaarylalkyl) aryl]alkanoic acids: A new class of specific LTA4 hydrolase inhibitors. J Med Chem 1992;35(17):3156-69
105. Hogg JH, Ollmann IR, Haeggstrom JZ, et al. Amino hydroxamic acids as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem 1995;3(10):1405-15
106. Yuan W, Munoz B, Wong CH, et al. Development of selective tight-binding inhibitors of leukotriene A4 hydrolase. J Med Chem 1993;36(2):211-20
107. Penning TD. Inhibitors of leukotriene A4 (LTA4) hydrolase as potential anti-inflammatory agents. Curr Pharm Des 2001;7(3):163-79
108. Tsuji F, Miyake Y, Enomoto H, et al. Effects of SA6541, a leukotriene A4 hydrolase inhibitor, and indomethacin on carrageenan-induced murine dermatitis. Eur J Pharmacol 1998;346(1):81-5
109. Tsuji F, Miyake Y, Horiuchi M, Mita S. Involvement of leukotriene B4 in murine dermatitis models. Biochem Pharmacol 1998;55(3):297-304
110. Thunnissen MM, Nordlund P, Haeggstrom JZ. Crystal structure of human leukotriene A4 hydrolase, a bifunctional enzyme in inflammation. Nat Struct Biol 2001;8(2):131-5
111. Sandanayaka V, Mamat B, Mishra RK, et al. Discovery of 4-[(2S)-2-{[4-(4- chlorophenoxy)phenoxy]methyl}-1- pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. J Med Chem 2010;53(2):573-85
112. Kirkland TA, Adler M, Bauman JG, et al. Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem 2008;16(9):4963-83
113. Rao NL, Dunford PJ, Xue X, et al. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J Pharmacol Exp Ther 2007;321(3):1154-60
114. Rao NL, Riley JP, Banie H, et al. Leukotriene A4 hydrolase inhibition attenuates allergic airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med 2010;181(9):899-907
115. Tian W, Jiang X, Tamosiuniene R, et al. Blocking macrophage leukotriene B4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med 2013;5(200):200ra117
116. Whittle BJ, Varga C, Berko A, et al. Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. Br J Pharmacol 2008;153(5):983-91
117. Hicks A, Monkarsh SP, Hoffman AF, Goodnow R. Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: Preclinical and clinical developments. Expert Opin Investig Drugs 2007;16(12):1909-20
118. Kuwabara K, Yasui K, Jyoyama H, et al. Effects of the second-generation leukotriene B4 receptor antagonist, LY293111Na, on leukocyte infiltration and collagen-induced arthritis in mice. Eur J Pharmacol 2000;402(3):275-85
119. Raychaudhuri A, Kotyuk B, Pellas TC, et al. Effect of CGS 25019C and other LTB4 antagonists in the mouse ear edema and rat neutropenia models. Inflamm Res 1995;44(Suppl 2):S141-2
120. Hoyer FF, Albrecht L, Nickenig G, Muller C. Selective inhibition of leukotriene receptor BLT-2 reduces vascular oxidative stress and improves endothelial function in ApoE-/- mice. Mol Cell Biochem 2012;359(1-2):25-31
121. Schmitt-Grohe S, Zielen S. Leukotriene receptor antagonists in children with cystic fibrosis lung disease : Anti-inflammatory and clinical effects. Paediatr Drugs 2005;7(6):353-63
122. Flamand L, Borgeat P, Lalonde R, Gosselin J. Release of anti-HIV mediators after administration of leukotriene B4 to humans. J Infect Dis 2004;189(11):2001-9
123. Hofheinz K, Kakularam KR, Adel S, et al. Conversion of pro-inflammatory murine Alox5 into an anti-inflammatory 15S-lipoxygenating enzyme by multiple mutations of sequence determinants. Arch Biochem Biophys 2012;530(1):40-7
124. Johansson AS, Haeggstrom JZ, Hultenby K, Palmblad J. Subcellular localization of leukotriene receptors in human endothelial cells. Exp Cell Res 2010;316(17):2790-6
125. Johansson AS, Haeggstrom JZ, Palmblad J. Commonly used leukotriene B4 receptor antagonists possess intrinsic activity as agonists in human endothelial cells. Effects on calcium transients, adhesive events and mediator release. Prostaglandins Leukot Essent Fatty Acids 2011;84(3-4):109-12
126. Rasmussen SG, DeVree BT, Zou Y, et al. Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 2011;477(7366):549-55